CLEVELAND (AP) — CLEVELAND (AP) — Sifco Industries Inc. (SIF) on Tuesday reported a loss of $443,000 in its fiscal fourth quarter. The Cleveland-based company said it had a loss of 8 cents per share.

Regeneron Pharmaceuticals got a modest confidence bump as Mirae Asset Global ETFs Holdings added 1,712 shares to their ...

DZ Bank has significantly reduced its holdings in Regeneron Pharmaceuticals, offloading 74.4% of its shares in Q4. Despite ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Revenues of ¥868.3 billion increased 7.8% year over year. The uptick was primarily driven by strong sales growth across all segments. (See the Zacks Earnings Calendar to stay ahead of market-making ...

We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in the US.

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price cut by BMO Capital Markets from $865.00 to $800.00 in a research note released on Wednesday morning,Benzinga reports.